Appia Bio Overview
- Year Founded
-
2020
- Status
-
Out of Business
- Employees
-
36
- Latest Deal Type
-
Out of Business
Appia Bio General Information
Description
Developer of a stem cell therapy technology intended to discover and develop chimeric antigen receptor-natural killer T(CAR-NKT) cells for safe and targeted cancer treatments for patients. The company's technology matures and scales up healthy stem cells into invariant T-cell therapies, enabling physicians to have access to allogeneic off-the-shelf cell therapies.
Contact Information
Website
www.appiabio.comCorporate Office
- 6160 Bristol Parkway
- Suite 300
- Culver City, CA 90230
- United States
Corporate Office
- 6160 Bristol Parkway
- Suite 300
- Culver City, CA 90230
- United States
Appia Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 26-Aug-2025 | Completed | Out of Business | |||
| 3. Early Stage VC (Series A1) | 30-Aug-2024 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 11-May-2021 | $55M | $55M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 01-Jan-2021 | Completed | Pre-Clinical Trials |
Appia Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Appia Bio Comparisons
Industry
Financing
Details
Appia Bio Competitors (4)
One of Appia Bio’s 4 competitors is Century Therapeutics, a Formerly VC-backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Century Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Adicet Bio | Formerly VC-backed | Boston, MA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA |
Appia Bio Patents
Appia Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025212997-A1 | Highly efficient and scalable production of engineered t cells from stem cells | Pending | 05-Apr-2024 | ||
| CA-3235379-A1 | Engineering stem cell t cells with multiple t cell receptors | Pending | 14-Oct-2021 | ||
| EP-4416271-A1 | Engineering stem cell t cells with multiple t cell receptors | Pending | 14-Oct-2021 | ||
| EP-4416271-A4 | Engineering stem cell t cells with multiple t cell receptors | Pending | 14-Oct-2021 | ||
| WO-2023064455-A1 | Engineering stem cell t cells with multiple t cell receptors | Inactive | 14-Oct-2021 | A61K40/11 |
Appia Bio Signals
Appia Bio FAQs
-
When was Appia Bio founded?
Appia Bio was founded in 2020.
-
Where is Appia Bio headquartered?
Appia Bio is headquartered in Culver City, CA.
-
What is the size of Appia Bio?
Appia Bio has 36 total employees.
-
What industry is Appia Bio in?
Appia Bio’s primary industry is Biotechnology.
-
Is Appia Bio a private or public company?
Appia Bio is a Private company.
-
What is Appia Bio’s current revenue?
The current revenue for Appia Bio is .
-
How much funding has Appia Bio raised over time?
Appia Bio has raised $75.5M.
-
Who are Appia Bio’s competitors?
Century Therapeutics, Nkarta Therapeutics, Adicet Bio, and Allogene Therapeutics are competitors of Appia Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process